key: cord-0844894-bqd19ppg
authors: Vodičar, Polona Maver; Valenčak, Anja Oštrbenk; Zupan, Blaž; Županc, Tatjana Avšič; Kurdija, Slavko; Korva, Miša; Petrovec, Miroslav; Demšar, Janez; Knap, Nataša; Štrumbelj, Erik; Vehovar, Vasja; Poljak, Mario
title: Low prevalence of active COVID-19 in Slovenia: a nationwide population study on a probability-based sample
date: 2020-07-18
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.07.013
sha: 4458552921007901b3087d42db5723b1476eaaf7
doc_id: 844894
cord_uid: bqd19ppg

OBJECTIVES: Accurate population-level assessment of the COVID-19 burden is fundamental for navigating the path forward during the ongoing pandemic, but current knowledge is scant. We conducted the first nationwide population study using a probability-based sample to assess active SARS-CoV-2 infection, combined with a longitudinal follow-up of the entire cohort over the next 6 months. Baseline SARS-CoV-2 RNA testing results and the first 3-week follow-up results are presented. METHODS: A probability-based sample of the Slovenian population (N = 2.1 million) was selected from the Central Population Register (n = 3,000). SARS-CoV-2 RNA was detected in nasopharyngeal samples using the cobas 6800 SARS-CoV-2 assay. Each participant filled in a detailed baseline questionnaire with basic sociodemographic data and current and past medical history compatible with COVID-19. After 3 weeks participants were interviewed for the presence of COVID-19–compatible clinical symptoms and signs, including in household members, and offered immediate testing for SARS-CoV-2 RNA if indicated. RESULTS: 1,368 (46%) individuals consented to participate and completed the questionnaire. Two of 1,366 participants tested positive for SARS-CoV-2 RNA (prevalence 0.15%; posterior mean 0.18%, 95% Bayesian CI 0.03–0.47%; 95% HDR 0.01–0.41%). No newly diagnosed infections occurred in the cohort during the first 3-week follow-up round. CONCLUSIONS: The low prevalence of active COVID-19 infections found in this study accurately predicted the dynamic of the epidemic in Slovenia over the subsequent month. Properly designed and timely executed studies using probability-based samples combined with routine target-testing figures provide reliable data for informed decisions on relaxing or strengthening mitigation strategies.

The Slovenian national study using a probability-based sample was planned in two phases 89 (Fig. 1 ). The first cross-sectional phase, which took place between April 20 and May 1, 2020, 90 was performed to determine the burden of active SARS-CoV-2 infections in the general 91 population that may have gone undetected within the past and current testing approaches and 92 epidemiological contact tracing. Selected persons were sent an invitation letter and a two-page 93 questionnaire by post about their household structure, their recent contacts and travel history, 94 and their own and household members' potential COVID-19-compatible symptoms 95 experienced in the past 2 months. According to General Data Protection Regulation (GDPR) 96 rules, we were only allowed to contact these persons using regular post and publicly available 97 landline and mobile telephone numbers. Respondents expressed their willingness via 98 telephone or email; however, in line with the study protocol, refusals were asked no further 99 questions, nor were they re-approached. Non-respondents were sent a reminder by post 1 100 week after the first invitation. The study design is shown in Fig. 1 . Interior and includes all permanent and temporary residents of Slovenia (Fig. 1) . The chosen 117 gross sample size (n = 3,000) matched the available resources and time limitations (1-2 weeks 118 of fieldwork) and was also sufficient for the study aims. The sampling design minimized 119 fieldwork costs, which involved ten to twelve trained medical teams with ambulances per day, 120 by selecting 300 census enumeration areas as primary sampling units. The selection of these 121 units followed the implicit stratification according to region and settlement type. Within each 122 unit, ten persons were randomly selected; data from the CPR on age, sex, region, and size and 123 type of settlement were also attached.

All study participants provided written informed consent; for participants under 18, previously described in detail [9] . Briefly, the sample was considered positive if either both 135 the ORF1 (target 1) and E (target 2) genes or only the ORF1 gene tested positive. Internal 136 validation showed assay's 100% sensitivity and 100% specificity [9] . The assay received U.S.

FDA Emergency Use Authorization on March 12, 2020. 

The response rate, adjusted for non-eligible persons, was 47% (AAPOR RR2) (Fig. 1) . The 149 study included 1,368 participants; 663 (48.5%) men and 705 (51.5%) women; the mean age 150 was 46.0 years (range 3 months to 99 years). Of these, 1,366 participants were tested for 151 SARS-CoV-2 RNA between April 20 and May 1, 2020. The sample matched the population 152 structure well; the differences in sex, region, and settlement type were not statistically 153 significant (χ ଶ , p > 0.01). The age structure was mismatched only for the age groups 0 to 10 154 years (7.3% instead of 11.0%) and 51 to 60 years (18.3% instead of 14.0%). However, due to 155 small differences, the weighting procedures have little effect, and -when optimizing the mean 156 squared error -the corresponding reduction in the bias component was smaller than the 157 related increase in the variance component due to weighting. Therefore, the study results, as 158 reported here, are based on the unweighted data. During detailed telephone medical consultation, for 22 participants it was jointly agreed not to 173 test for SARS-CoV-2 RNA due to the high probability that the symptoms recalled were linked 174 with other medical conditions. Finally, seven participants were tested for SARS-CoV-2 RNA 175 and all were negative. In addition, five participants informed us that they sought testing for sample (0.15%) (Fig. 2) . In addition to the Icelandic and Slovenian studies, our intensive Furthermore, such approach has limited potential to detect smaller focal outbreaks, and is 250 probably most appropriate in environment with low viral circulation. Additional limitation is 251 11 that negative SARS-CoV-2 RNA testing result does not necessarily rule out COVID-19 if 252 sample is taken during diagnostic window or in case of suboptimal quality of sampling. 253 Lastly, non-respondents could present potential limitation of our study. However, the study 254 sample matched the population structure well and weighting did not change the prevalence 255 estimates. Additionally, for non-response bias there must exist a content-specific missing 256 data mechanism linking participation with prevalence, and there is little evidence to support 257 the assumption that persons who are more likely to be infected might also be more willing to 258 participate. Thus we believe that non-response bias in the present study is relatively small and 259 the study reliably estimated the true prevalence of active COVID-19 infection in Slovenia.

Properly designed and executed studies using probability-based samples combined with 

Clinical features of patients infected 329 with 2019 novel coronavirus in Wuhan, China

A pneumonia outbreak 332 associated with a new coronavirus of probable bat origin

A novel coronavirus from patients 335 with pneumonia in China

Interrupting transmission of COVID-19: lessons from 338 containment efforts in Singapore

New Zealand's 341 elimination strategy for the COVID-19 pandemic and what is required to make it work

New Zealand eliminates COVID-19

Response to COVID-19 in Taiwan: big data analytics, new 347 technology, and proactive testing

Reopening society and the need for real-time 350 assessment of COVID-19 at the community level

Clinical 353 evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in 354 the midst of the COVID-19 pandemic

RStan: the R interface to Stan. R package version 2.19.1

Detection of 360 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Population-based age-stratified seroepidemiological investigation protocol for 363 COVID-19 virus infection

Seroepidemiology-2020.1-eng.pdf

Spread of SARS-CoV-2 in the Icelandic population

SARS-CoV-2-specific antibodies among adults in

COVID-19 Prävalenzstudie: maximal 0,15% der Bevölkerung in 375 Österreich mit SARS-CoV-2 infiziert

SORA. Studienberichte zur 1. SARS-CoV-2

Quality report for the European 383

London: European Social Survey ERIC 2014. Österreichische 384 Bundesminsterium

Prevalence of SARS-CoV-2 infection in the Luxembourgish population -the CON-VINCE 390 study

Research on covid-19 is suffering "imperfect incentives at every stage". 393

Assuring research integrity during a 396 pandemic

Double-edged spike: are SARS-CoV-2 serological tests safe right 400 now?

The promise and peril of antibody testing for COVID-19

Interim Guidelines for COVID-19 Antibody Testing

Waiting for certainty on Covid-19 410 antibody tests -at what cost?

CDC COVID-19 Response Team

Evidence for limited early spread of COVID-19 within the United States